$46.18
-0.20 (-0.43%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where CDNA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional · 13 observational
Held by 14 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, D. E. Shaw & Co., Inc., First Eagle Investment Management, LLC, JANE STREET GROUP, LLC, TWO SIGMA INVESTMENTS, LP, +9 more) · FINRA short interest 4.3 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 6 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Forecasting Relapse Outcomes With AlloHeme-based Risk Detection in Post-Allo-HCT AML/MDS Patients (FORWARD)NCT07607327observationalTo evaluate AlloHeme test performance in predicting post-transplant relapse (by FDA criteria) or any cytogenetic/molecular evidence of disease resulting in unplanned treatment intervention in AML and MDS patients. | — | Not yet recruiting | Diagnostic test: AlloHeme | AML (Acute Myelogenous Leukemia), MDS (Myelodysplastic Syndrome), CMML | 400 | 2029-12-31 | in 1,230 d | 2026-05-26 |
| AlloSure Lung Assessment and Metagenomics Outcomes StudyNCT05050955observationalALAD | — | Active, not recruiting | — | Lung Transplant Infection, Lung Transplant; Complications, Lung Transplant Failure and Rejection | 550 | 2028-12-31 | in 865 d | 2026-06-25 |
| Molecular Assessment and Profiling of Liver Transplant RecipientsNCT04793360observationalTo correlate the results of LiverCare with clinically significant events impacting post-transplant clinical outcomes, histological findings, and the development of de novo Donor Specific Antibody (DSA) | — | Active, not recruiting | Device: LiverCare | Liver Transplantation, Biomarkers | 1,500 | 2027-12-31 | in 499 d | 2026-02-23 |
| Surveillance HeartCare® Outcomes RegistryNCT03695601observationalProportion of patients who develop de-novo DSA as a surrogate to clinical outcomes at 1, 3 and 5 years post-transplant. | — | Active, not recruiting | Other: Standard of Care | Heart Transplant Rejection | 2,743 | Nov 2026 | ≤ 103 d | 2026-05-27 |
| HeartCare Immuno-optimization in Cardiac Allografts (MOSAIC)NCT05459181Incidence of Allograft loss at 12-months post-transplant (safety)Randomized · Open-label · Treatment | Not applicable | Not yet recruiting | Diagnostic test: HeartCare | Heart Transplant, Immunosuppression, Allograft | 930 | Sep 2026 | ≤ 42 d | 2024-10-23 |
| Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme TestNCT04635384observationalTo determine the association between increased mixed chimerism (iMC) detected by AlloHeme and post-transplant relapse in patients with acute leukemia and myelodysplastic syndrome. | — | Active, not recruiting | — | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome | 307 | 2026-05-31 | — | 2026-03-18 |
| Evaluation of Patient Outcomes From the Kidney Allograft Outcomes AlloSure RegistryNCT03326076observationalInterstitial fibrosis/tubular atrophy (IF/TA) quantified by Banff Working Group biopsy grade(s) at 12 months post-transplant in AlloSure® and renal allograft biopsy managed patients | — | Unknown status | Diagnostic test: Donor-derived cell-free DNA (AlloSure®), Peripheral blood gene expression profiling (AlloMap Kidney), Analytic platform (IBox) · Other: Standard care | Kidney Transplant Rejection | 4,000 | 2025-06-30 | — | 2023-06-27 |
| Transition of Renal Patients Using AlloSure Into Community Kidney CareNCT04601155observationalSuperior allograft survival | — | Completed | Device: AlloSure | Kidney Transplant Rejection | 248 | 2023-03-24actual | — | 2023-11-03 |
| KidneyCare Immuno-optimization in Renal Allografts (KIRA)NCT05423496Estimated glomerular filtration rate (eGFR) at 12 months, non-inferiorityRandomized · Open-label · Treatment | Not applicable | Withdrawnsponsor's stated reason: Business decision based on clinical utility considerations | Diagnostic test: KidneyCare · Drug: steroid, MMF | Kidney Transplant, Immunosuppression, Allograft | 0 | 2023-02-23 | — | 2023-03-27 |
| Technology Enabled And Molecular Monitoring of the Allograft and Transplant rEcipientNCT05033548observationalOverall reduction in Readmission Rate to hospital within 90 days (all causes) | — | Terminatedsponsor's stated reason: Decision by Sponsor after careful review of study data available. | — | Transplant | 246 | 2023-02-02actual | — | 2023-08-30 |
| AlloSure Guided Immuno-Optimization for COVID-19: An Early ExperienceNCT04341103observationalAssessing the utility of AlloSure dd-cfDNA to guide clinical immune-optimization for transplant patients with COVID-19 | — | Unknown status | — | Solid Organ Transplant Rejection, COVID-19 | 500 | 2020-12-01 | — | 2020-04-10 |
| Assessing AlloSure Dd-cfDNA Monitoring Insights of Renal Allografts With Longitudinal SurveillanceNCT04566055observationalValidation of AlloSure in Allograft rejection | — | Unknown status | Device: AlloSure | Kidney Transplant Rejection | 1,000 | 2020-10-01 | — | 2020-10-05 |
| Outcomes AlloMap Registry: the Long-term Management and Outcomes of Heart Transplant Recipients With AlloMap TestingNCT01833195observationalVital status of heart transplant recipient | — | Unknown status | — | Cardiac Transplant Failure, Cardiac Transplant Rejection, Heart Diseases | 2,444 | Feb 2020 | — | 2020-02-05 |
| Utility of Donor-Derived Cell Free DNA in Association With Gene Expression ProfilingNCT02178943observationalClinical Outcomes (Vital Status of Heart Transplant Recipients) | — | Completed | — | Cardiac Transplant Failure, Cardiac Transplant Rejection, Heart Diseases | 100 | Dec 2019actual | — | 2024-10-29 |
| Non Invasive Blood Test To Diagnose Acute Rejection After Kidney TransplantationNCT02424227observationalClinical T cell as well as antibody mediated acute rejection | — | Unknown status | — | Kidney Transplant Recipients | 401 | 2018-08-30actual | — | 2018-12-17 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19